A five-year study from Queen Mary University of London found zero deaths from cervical cancer among women aged 20–24 in England. The research confirms that the national immunization strategy, which began in 2008, has had a significant impact, preventing an estimated 200 deaths among women aged 25–34.
How the HPV Vaccine Prevents Cancer
The HPV vaccine works by training the immune system to recognize and neutralize specific strains of the human papillomavirus. While most HPV infections are cleared naturally by the immune system, certain "high-risk" types can lead to persistent infections that cause cellular changes in the cervix, eventually progressing to cancer.
According to the Centers for Disease Control and Prevention (CDC), the vaccine protects against nine high-risk strains of the virus. By preventing these initial infections, the vaccine stops the biological sequence that leads to cervical, vaginal, vulvar, anal, head, neck, and throat cancers. In the United States, the CDC recommends the vaccine series for children at age 11 or 12, though it can be given as early as age 9. The vaccine is approved for individuals up to age 45.
Impact of the England Vaccination Program
The success observed in England provides a clear look at the long-term effectiveness of widespread immunization. The program began in 2008, targeting girls aged 12 and 13, and achieved high coverage rates of 80% to 90% in the initial years.
Professor Peter Sasieni, lead researcher at Queen Mary University of London, noted that the current data represents only the beginning of the vaccine’s protective impact. As reported by the BBC, Sasieni stated that as vaccinated generations age, the number of prevented deaths will likely grow significantly, with projections suggesting as many as 18,000 deaths prevented. Researchers estimated that without the vaccination program, there would have been approximately 23 deaths from cervical cancer in the 20–24 age group during the study period.
Current Vaccination Trends and Challenges
Despite the documented success of the vaccine, public health officials have raised concerns regarding declining uptake. Both England and the United States experienced a decrease in routine adolescent vaccination rates during the pandemic, and neither nation has fully returned to pre-pandemic levels.
Public health strategies continue to emphasize two pillars for eradication:
- Widespread Vaccination: Helps us eliminate cervical cancer deaths.
- Regular Screening: Cervical cancer screenings can help identify HPV infection and changes to the cervix before they cause cancer.
Frequently Asked Questions
Who should receive the HPV vaccine?
The CDC recommends the vaccine for all adolescents aged 11 or 12, though it can be administered starting at age 9. The CDC recommends catch up vaccinations for people 26 and under who didn’t get the vaccine when they were teenagers. The vaccine is approved for individuals up to age 45.
Does the vaccine protect against all types of HPV?
No. The vaccine protects against nine high-risk strains of the virus. Because it does not cover every possible strain, regular screening for cervical cancer can help identify HPV infection and changes to the cervix before they cause cancer.
Is the vaccine effective if I am already sexually active?
The sources do not provide information on the vaccine’s efficacy for individuals who are already sexually active.
Why are vaccination rates dropping?
The sources do not provide specific expert suggestions on why vaccination rates are dropping beyond noting that both countries saw a drop during the pandemic and neither has seen them bounce back all the way.
Related reading